Comparative speed of kill of sarolaner (Simparica™ Chewables) and fluralaner (Bravecto®) against induced infestations of Amblyomma americanum on dogs by Robert H. Six et al.
RESEARCH Open Access
Comparative speed of kill of sarolaner
(Simparica™ Chewables) and fluralaner
(Bravecto®) against induced infestations
of Amblyomma americanum on dogs
Robert H. Six1*, David R. Young2, Melanie R. Myers1 and Sean P. Mahabir1
Abstract
Background: The lone star tick, Amblyomma americanum, infests dogs and cats in North America and transmits the
pathogens Ehrlichia chaffeensis and Ehrlichia ewingii, which cause monocytic and granulocytic ehrlichiosis in dogs
and humans, and Cytauxzoon felis which causes cytauxzoonosis in cats. A parasiticide’s speed of kill is important to
minimize the direct deleterious effects [related to blood-feeding] of tick infestation and reduce the risk of transmission
of tick-borne pathogens. In this study the speed of kill of sarolaner (Simparica™ Chewables) administered monthly for
3 months against A. americanum on dogs was evaluated and compared with a single dose of fluralaner (Bravecto®) for
13 weeks.
Methods: Based on pretreatment tick counts, 24 dogs were randomly allocated to treatment with placebo or
sarolaner at the label rate (2 to 4 mg/kg) on Days 0, 30 and 60 or with fluralaner (25 to 56 mg/kg) once according to
manufacturer’s instructions on Day 0. Dogs were examined and live ticks counted at 8, 12, and 24 h after treatment
and subsequent re-infestations on Days 14, 28, 42, 58, 76 and 90. Acaricidal efficacy was determined at each time point
relative to counts for placebo dogs.
Results: Monthly oral doses of sarolaner provided > 95 % efficacy within 24 h of treatment, and consistently
provided > 70 % efficacy against subsequent re-infestations with ticks within 24 h over the entire treatment
period. Significantly more live ticks were recovered from fluralaner-treated dogs than from sarolaner-treated
dogs at 24 h after re-infestation from Day 42 onwards. At 24 h, efficacy of fluralaner was ≤ 20 % from Day
42 to the end of the study on Day 90. There were no adverse reactions to treatment.
Conclusions: In this controlled laboratory evaluation, monthly treatment with sarolaner provided consistent
efficacy against A. americanum with > 70 % of ticks killed within 24 h after a single oral dose over the duration of the
study. Monthly treatment with sarolaner consistently killed significantly more ticks within 24 h than a single dose of
fluralaner from 6 weeks after initial treatment.
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Background
Pet owners and veterinarians recognize ticks to be both
a nuisance and a threat to animal and human health; in-
festations cause direct damage as a result of tick feeding
behavior, and ticks transmit pathogens of veterinary and
zoonotic importance [1]. The lone star tick, Amblyomma
americanum, can bite humans, livestock, dogs and cats
as well as many other mammals, and is one of the most
common tick species infesting dogs in North America
[2]. Its geographic range has expanded from the southern
states [3], across the southern plains, through the Midwest
and into the eastern states. Focal populations have also
been reported in northern states including Maine, New
York, Massachusetts, Connecticut and New Jersey [4, 5].
Amblyomma americanum transmits Ehrlichia chaffeensis
and Ehrlichia ewingii [2, 6] to dogs and humans,
which cause monocytic and granulocytic ehrlichiosis,
respectively, and Borrelia lonestari, a probable cause
of erythema migrans in humans, has also been de-
tected in A. americanum using DNA amplification tech-
niques [7].
Tick prevention and control have taken on a new
importance as the awareness of, and exposure to, tick-
borne diseases increases and A. americanum (and other
tick species) populations expand. Topically administered
parasiticides with contact activity have traditionally been
the most commonly used approach for tick control on
dogs, but recently a new class of compounds, the iso-
xazolines, have demonstrated efficacy against ticks for
1 month or longer following a single oral dose [8–10].
Sarolaner has demonstrated > 95 % efficacy against A.
americanum within 48 h after re-infestation for 35 days
[10], while afoxolaner has been reported to provide
≥ 98.9 % efficacy against A. americanum for up to 30 days
after a single dose when assessed at 72 h after infestation
[11]. Another isoxazoline, fluralaner, has demonstrated
> 90 % efficacy against A. americanum for only 8 weeks
when assessed at 72 h after infestation [12].
The speed of acaricidal activity is critical in disrupting
or preventing feeding of ticks, thus reducing the risk of
pathogen transmission. While pathogen transmission
generally occurs after the infected tick is attached and
feeds for at least 24 to 48 h [13, 14], transmission of
Ehrlichia canis by Rhipicephalus sanguineus has re-
cently been shown to occur within as little as 3 h after
attachment under laboratory conditions [15]. Sarolaner
in a chewable tablet formulation (Simparica™ Chewables)
provides control of fleas and ticks for at least 1 month
after a single oral dose [16]. Here we report a labora-
tory study conducted to evaluate and compare the
speed of kill of a monthly oral dose of sarolaner with
a single oral dose of fluralaner (Bravecto®) against an
existing infestation and against re-infestations with A.
americanum over a period of 90 days.
Methods
The study was a masked, negative controlled, random-
ized laboratory comparative efficacy study conducted in
California, USA. Study procedures were in accordance
with the World Association for the Advancement of
Veterinary Parasitology (WAAVP) guidelines for evaluat-
ing the efficacy of parasiticides for the treatment, pre-
vention and control of flea and tick infestation on dogs
and cats [17], and complied with the principles of Good
Clinical Practices [18]. Masking of the study was assured
through the separation of functions. All personnel con-
ducting observations or animal care or performing infes-
tations and counts were masked to treatment allocation.
Animals
Thirteen male and 11 female, purpose-bred Beagles from
34 to 58 months of age and weighing from 8.6 to
13.2 kg were included in the study. Each dog was indi-
vidually identified by a unique ear tattoo or electronic
transponder and had undergone an adequate wash-out
period to ensure that no residual ectoparasiticide efficacy
remained from any previously administered treatments
as demonstrated by live tick retention at the host suit-
ability evaluation. Dogs were individually housed in in-
door runs that conformed to accepted animal welfare
guidelines and ensured no direct contact between dogs.
Dogs were acclimatized to these conditions for at least
14 days prior to treatment. Dogs were fed an appropriate
maintenance ration of a commercial dry canine feed for
the duration of the study. Water was available ad
libitum. All dogs were given a physical exam to en-
sure that they were in good health at enrollment and suit-
able for inclusion in the study. General health observations
were performed at least once daily throughout the study.
Design
The study followed a randomized complete block design.
Twenty four dogs were ranked according to decreasing
tick counts into blocks of 3, and within each block dogs
were randomly allocated to treatment with placebo,
sarolaner, or fluralaner, resulting in 8 dogs in each treat-
ment group. Tick counts were conducted at 8, 12 and
24 h after treatment and each subsequent re-infestation.
Treatment
On Days 0, 30 and 60, two groups of dogs each received
either a placebo tablet or an appropriate Simparica™
Chewable tablet to provide the label dose (sarolaner at 2
to 4 mg/kg). The third group of dogs received a
Bravecto® tablet (per label providing fluralaner at 25 to
56 mg/kg) on Day 0 and placebo tablets on Days 30 and
60. All dogs were fed their regular ration within 30 min
prior to treatment administration on Day 0 in order to
comply with Bravecto® label directions. The tablet(s)
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were administered by hand pilling to ensure accurate
and complete dosing. Each dog was observed for several
minutes after dosing for evidence that the dose was
swallowed, and for general health at 1, 4, and 24 h after
treatment administration, and at least once daily for the
duration of the study. Dogs were observed approxi-
mately two hours after dosing for evidence of emesis.
Tick infestation and assessment
The ticks were obtained from the Oklahoma State
University’s A. americanum colony, which was initi-
ated in 1976 with engorged females collected locally
in Stillwater, OK. The colony has been maintained
with the introduction of locally collected, engorged
females every 2 years. The most recent introduction
was approximately 4 months before the study was ini-
tiated. Ticks were considered pathogen free, as the
unfed adult ticks used in this study had been main-
tained for at least one generation in the colony on
pathogen-free hosts.
Tick infestations were performed on Days -9 (host
suitability and allocation), -2, 14, 28, 42, 58, 76 and 90.
For each infestation dogs were sedated with a combin-
ation of ketamine and xylazine, a pre-counted aliquot of
50 (±5; 1:1 sex ratio) viable unfed adult A. americanum
was directly applied to the dog, which was then confined
in an appropriately sized travel crate for approximately
4 h to restrict movement and facilitate tick attachment.
Each dog was examined to remove and count live ticks
at 48 h after the initial host suitability infestation. At 8
and 12 (±1) hours after treatment and each subsequent
re-infestation, the dogs were examined systematically so
that the entire body surface was carefully examined and
live ticks were counted in situ. At 24 h after treatment
and each subsequent re-infestation, the dogs were exam-
ined and then thoroughly combed to count and remove
live ticks. Each dog was examined for at least 10 min. If
ticks were encountered in the last minute, combing was
continued in 1 min increments until no ticks were
encountered.
Statistical analysis
The individual dog was the experimental unit and the
primary endpoint was the live tick count. Data for
post-treatment live (free plus attached) tick counts
were summarized with arithmetic (AM) and geomet-
ric (GM) means by treatment group and time point.
Tick counts were transformed by the loge(count + 1)
transformation prior to analysis in order to stabilize
the variance and normalize the data. Using the PROC
MIXED procedure (SAS 9.2, Cary NC), transformed
counts were analyzed using a mixed linear model.
The fixed effects were treatment, time point and the
interaction between time point and treatment by time
point. The random effects included block, block by treat-
ment interaction and error. Testing was two-sided at the
significance level α = 0.05.
The assessment of efficacy for live ticks was based on
the percent reduction in the arithmetic and geometric
mean live tick counts relative to placebo and to the posi-
tive control, as suggested by the most recent guidelines
of the WAAVP for systemic acaricides [17] and was cal-
culated using Abbott’s formula:
% reduction ¼ 100  mean count placeboð Þ–mean count treatedð Þ
mean count placeboð Þ
Results
There were no treatment-related adverse events during
the study. Placebo-treated dogs maintained tick infesta-
tions throughout the study with mean tick counts ran-
ging from approximately 10 to 25 (Tables 1, 2 and 3).
At the 8-h time point, tick counts for both products
were not significantly different from placebo-treated
dogs or each other (P ≥ 0.1177) at any evaluation except
on Day 0 when counts for the fluralaner-treated dogs
were significantly lower than placebo (P = 0.0218) but no
different to those for sarolaner treated dogs (P = 0.5337).
Efficacy at Day 0 was 45.0 % for fluralaner and 33.2 %
for sarolaner and subsequent percent reductions
ranged from 0 to 33.8 % for fluralaner and 0 to
34.7 % for sarolaner (GM) (Table 1).
At the 12-h time point, sarolaner-treated dogs had sig-
nificantly lower tick counts than placebo-treated dogs
(P < 0.0001) on Day 0 with efficacy (GM) of 76.0 %
(Table 2). Treatment with fluralaner resulted in signifi-
cantly lower tick counts than placebo at 12 h on Days 0
and 14 (P ≤ 0.0038) with efficacies (GM) of 53.4 and
61.4 %, respectively. Tick counts for sarolaner were sig-
nificantly lower than for fluralaner on Day 0 (P = 0.0440)
and similar on Day 14 (P = 0.0750) with efficacies of 76.0
and 27.5 % respectively. The tick counts were similar for
placebo, sarolaner and fluralaner-treated dogs on all
other count days (P ≥ 0.0966) and percent reductions
ranged from 0.0 to 35.9 % for fluralaner and 7.5 to
36.6 % for sarolaner (GM) (Table 2).
At the 24-h time point, dogs treated with sarolaner
had significantly lower tick counts than placebo-treated
dogs (P < 0.0001) on all count days, and these counts
were also lower than those for fluralaner-treated dogs
(P ≤ 0.0006) from Day 42 to Day 90 (Table 3).
Fluralaner-treated dogs had significantly lower tick
counts than placebo (P < 0.0001) from Day 0 to Day 28
only. Treatment with sarolaner resulted in efficacy of at
least 71.3 % (GM) to Day 90, while efficacy for dogs
treated with fluralaner declined below 20 % (GM) and
was no different from placebo (P ≥ 0.4870) from Day 42
to Day 90 (Table 3, Fig. 1).
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Table 1 Mean live Amblyomma americanum counts and efficacy relative to placebo at 8 hours after treatment and post-treatment
re-infestations for dogs treated with oral sarolaner on Days 0, 30, and 60 or fluralaner once on Day 0
Treatment Day of treatment or re-infestation
0 14 28 42 58 76 90
Placebo Range 17–31 4–18 7–24 9–28 9–30 8–26 7–23
A. mean 23.5 11.6 15.1 15.8 19.9 16.1 17.5
G. mean1 23.1a 10.6a 13.6a 14.6a 18.8a 15.0a 16.6a
Sarolaner Range 6–28 2–15 7–20 9–34 6–18 3–22 10–24
A. mean 16.8 9.3 12.0 17.3 12.8 14.4 16.1
Efficacy (%) 28.7 20.4 20.7 0.0 35.8 10.9 7.9
G. mean1 15.4a,b 7.8a 11.4a 15.9a 12.3a 12.7a 15.5a
Efficacy (%) 33.2 26.3 16.1 0.0 34.7 15.3 6.7
P-value vs placebo 0.1338 0.2817 0.5240 0.7543 0.1177 0.5432 0.7973
Fluralaner Range 2–30 2–17 8–18 5–26 12–27 7–19 11–30
A. mean 16.3 8.1 14.1 19.5 16.6 13.3 17.0
Efficacy (%) 30.9 30.1 6.6 0.0 16.4 17.8 2.9
G. mean1 12.7b 7.0a 13.6a 17.7a 16.1a 12.7a 16.2a
Efficacy (%) 45.0 33.8 0.4 0.0 14.0 15.7 2.6
P-value vs placebo 0.0218 0.1317 0.9883 0.4619 0.5580 0.5149 0.9203
P-value vs sarolaner 0.5337 0.7457 0.5867 0.7321 0.3792 0.9889 0.8883
1Geometric means within columns with the same superscript are not significantly different (P > 0.05)
Table 2 Mean live Amblyomma americanum counts and efficacy relative to placebo at 12 hours after treatment and post-treatment
re-infestations for dogs treated with oral sarolaner on Days 0, 30, and 60 or fluralaner once on Day 0
Treatment Day of treatment or re-infestation
0 14 28 42 58 76 90
Placebo Range 18–32 3–17 7–23 3–27 6–28 7–27 7–25
A. mean 24.1 10.5 15.1 14.3 18.4 14.5 17.3
G. mean1 23.8a 9.3a 13.9a 12.4a 17.2a 13.0a 16.4a
Sarolaner Range 2–15 2–14 8–20 6–24 7–16 3–22 9–23
A. mean 7.3 7.8 11.9 12.6 11.3 11.9 13.9
Efficacy (%) 69.9 26.2 21.5 11.4 38.8 18.1 19.6
G. mean1 5.7c 6.7a,b 11.3a 11.5a 10.9a 9.8a 13.2a
Efficacy (%) 76.0 27.5 18.3 7.5 36.6 24.6 19.0
P-value vs placebo < 0.0001 0.2624 0.4612 0.7786 0.0972 0.3085 0.4375
Fluralaner Range 3–29 0–14 2–19 5–36 15–17 5–19 11–28
A. mean 13.5 5.1 10.5 21.3 15.8 12.0 16.4
Efficacy (%) 44.0 51.2 30.6 0.0 14.3 17.2 5.1
G. mean1 11.1b 3.6b 8.9a 19.1a 15.7a 11.0a 15.6a
Efficacy (%) 53.4 61.4 35.9 0.0 8.7 15.6 4.8
P-value vs placebo 0.0038 0.0012 0.0966 0.1010 0.7241 0.5211 0.8494
P-value vs sarolaner 0.0440 0.0750 0.4523 0.1060 0.2476 0.7240 0.6037
1Geometric means within columns with the same superscript are not significantly different (P > 0.05)
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Discussion
Sarolaner provided a significant reduction in A. ameri-
canum tick counts within 12 h after the first treatment
on Day 0 and demonstrated consistently high efficacy of
> 70 % (GM) within 24 h after re-infestations over the
three month (three dose) period. In contrast, a single
dose of fluralaner only provided significant reductions in
tick counts through Day 28 when assessed up to 24 h
after infestation and counts at 24 h were no different to
placebo from Day 42 onwards. Thus, monthly treatment
with sarolaner resulted in a consistent speed of kill of A.
americanum ticks over the three month period, while
the speed of kill of fluralaner was significantly lower
from Day 42 with counts no different from placebo at
24 h after infestation. These results are consistent with
the reported performance of the two products; sarolaner
provides efficacy ≥ 96.5 % within 48 h for 35 days after a
single dose against five tick species [10] and ≥ 89.6 % ef-
ficacy against re-infestations of Amblyomma maculatum
within 24 h for 35 days [19]. Fluralaner has efficacy
Table 3 Mean live Amblyomma americanum counts and efficacy relative to placebo at 24 hours after treatment and post-treatment
re-infestations for dogs with oral sarolaner on Days 0, 30, and 60 or fluralaner once on Day 0
Treatment Day of treatment or re-infestation
0 14 28 42 58 76 90
Placebo Range 19–31 3–18 8–21 7–37 10–32 6–26 8–21
A. mean 24.6 10.8 13.1 17.4 19.8 14.9 16.5
G. mean1 24.4a 9.4a 12.6a 15.5a 18.7a 13.4a 15.7a
Sarolaner Range 0–7 0–2 0–10 0–10 2–14 0–5 0–9
A. mean 0.9 1.0 3.6 2.8 6.1 1.1 2.6
Efficacy (%) 96.4 90.7 72.4 84.2 69.0 92.4 84.1
G. mean1 0.3b 0.8b 2.1b 1.3b 5.4b 0.8b 1.7b
Efficacy (%) 98.8 91.6 83.1 91.6 71.3 94.3 89.4
P-value vs placebo < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001 < 0.0001
Fluralaner Range 0–4 0–9 0–11 6–32 13–24 7–18 7–26
A. mean 0.9 2.6 3.4 19.1 16.9 11.6 15.9
Efficacy (%) 96.4 75.6 74.3 0.0 14.6 21.8 3.8
G. mean1 0.5b 1.4b 2.2b 17.4a 16.6a 11.2a 14.8a
Efficacy (%) 97.8 85.2 82.4 0.0 11.5 16.8 5.8
P-value vs placebo < 0.0001 < 0.0001 < 0.0001 0.6487 0.6360 0.4870 0.8182
P-value vs sarolaner 0.5715 0.3246 0.9247 < 0.0001 0.0006 < 0.0001 < 0.0001































Fig. 1 Percent efficacy based on geometric mean counts relative to placebo at 24 hours after treatment and weekly post-treatment re-infestations of
Amblyomma americanum for dogs treated with oral sarolaner on Days 0, 30, and 60 or fluralaner once on Day 0. *Geometric mean live tick counts for
sarolaner significantly lower than those for fluralaner (P≤ 0.05)
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against Dermacentor variabilis, Ixodes scapularis and R.
sanguineus for up to 12 weeks after a single dose based
on counts at 48 h, but only 8 weeks of persistent efficacy
versus A. americanum when assessed at 72 h after in-
festation [12]. These results also concur with a previous
study in which the speed of kill of fluralaner against R.
sanguineus and Dermacentor reticulatus similarly de-
creased in the third month after treatment [20].
On Day 42, the efficacy of sarolaner and flurolaner at
the 8 and 12 h time points ranged from 0.0 to 7.5 %
(GM). The reason for this apparent lower efficacy of
both products relative to the same time points on other
Days is unknown. Because the effect was observed with
both products, and the tick counts on the placebo-
treated dogs were generally consistent with those from
other post-treatment infestations, it is plausible that
there was a relatively prolonged period of time between
tick infestation and the initiation of tick feeding, which
resulted in delayed drug exposure. This can happen if
ticks are not held for sufficient time after molting from
the previous stage to allow optimal priming for feeding.
This results in ticks questing longer and taking add-
itional time to attach and commence blood feeding.
The perceived benefit of a longer treatment interval
(such as 8 to 12 weeks for fluralaner) and hence the
need for less treatments, needs to be balanced with the
potential risk of an unpredictable decline in efficacy at
the end of the claimed treatment period. Also, the vari-
ability in efficacy and the duration of the period of pro-
tection provided by fluralaner against different tick
genera and species could be confusing for prescribers
and users who may not be familiar with the ticks in their
region. An important benefit of monthly sarolaner ad-
ministration is that it provides sustained efficacy against
relevant tick species in dogs and maintains a consistent
speed of kill for the entire duration of the month. Rapid
and consistent kill of ticks is important to reduce the
direct adverse effects of tick feeding and is critical in the
reduction of tick-borne pathogen transmission. Thus,
the consistent efficacy of a single oral dose of sarolaner
shown in this study should help to reduce the risk of
a treated dog on a monthly treatment regime becom-
ing infected with the pathogens transmitted by A.
americanum. Further studies directly examining the
effect of treatment on the transmission and infectivity
of these individual pathogens are needed to confirm
the levels of protection provided through sarolaner’s
acaricidal efficacy.
Conclusions
This study confirmed the consistent acaricidal efficacy of
monthly treatment with sarolaner against A. americanum
and demonstrated that >70 % of ticks were killed within
24 h during the entire treatment period. Monthly treat-
ment with sarolaner killed significantly more ticks within
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